By Scott Shaunessy, Founder and CEO of ideaPoint
As COVID-19 continues to take a toll worldwide, it is more important than ever to provide pharmaceutical and biotech companies with the tools they need to work towards better therapies and, eventually, a cure for the potentially deadly disease which has infected over a million people around the globe.
We at ideaPoint work to provide medical affairs and innovation management solutions, which puts us in a unique position at the forefront of the effort to defeat COVID-19, partnering with major pharmaceutical companies. Our software solutions help pharma companies manage medical affairs programs in a secure and compliant manner, and our partnering and innovation sourcing tools accelerate the speed of identifying, evaluating, tracking, and managing innovation through internal and external partnerships and collaborations.
ideaPoint helps pharma companies share clinical trial data, run Early Access Programs, investigator-initiated studies, and more. Our software can be configured to adapt to any company’s SOP for managing the highly-regulated process of evaluating, approving, tracking, and reporting on Medical Affairs Programs in a secure and compliant manner.
Recently, we announced our partnership with clinical data company WideTrial to make investigational medicines more accessible to hospitals dealing with COVID-19 around the world. The goal of this collaboration is to establish a unifying hub from which companies who create potentially effective drugs to treat COVID-19 can make their product available to a large number of people through Expanded Access Programs or EAPs. EAPs are specially authorized clinical trials approved by the U.S. Food and Drug Administration to allow “treatment-use” of pre-market drugs by patients and their healthcare providers who cannot participate in regular clinical trials.
As a company closely tied to the Life Sciences industry, we are supporting the pharmaceutical industry in their fight against COVID-19. Read on to learn more about three major companies working with us here at ideaPoint who are on the front lines of the effort to diagnose, treat, and prevent infections of the novel Coronavirus.
Abbott Laboratories is a health care, medical devices, and pharmaceutical company based in Illinois. For over 130 years, Abbott Laboratories has been pioneering solutions in the medical arena. Notably, they recently launched a test for COVID-19 – the Abbott ID NOW COVID-19 test – which allows patients to see their test results in five minutes. The test can be used in physicians’ offices and urgent care clinics for quick and convenient testing. Abbott Laboratories’ test is the fastest available point-of-care test for detecting the novel coronavirus (COVID-19).
Idea-sharing is essential to the rapid development of new technologies and treatments for COVID-19, especially as new information becomes available about this novel, yet worldwide, disease. That’s why we at ideaPoint are at the forefront of this effort, developing an internally-facing portal for Abbott Laboratories. This portal is used to solicit ideas from global employees to accelerate the pace of innovation and drive more novel solutions like the Abbott ID NOW COVID-19 test. This portal can be used to obtain feedback on solutions to help patients directly, to help Abbott Labs partner with other organizations, or to help them participate in public health initiatives. Abbott Laboratories is open to all ideas; they will then use ideaPoint to screen the ideas and decide which ideas they can support. With no shortage of ideas, Abbott is sure to remain at the forefront of the fight against COVID-19.
Global Blood Therapeutics (GBT) is a California-based pharmaceutical company engaged in the effort against COVID-19 by supporting people with a serious disease known as sickle cell anemia. GBT’s work is focused on improving treatment and care for patients with sickle cell disease, and they have stepped up their efforts to take care of sickle cell patients, who face more serious complications from COVID-19, during this time. For example, GBT is working to ensure that patients can have uninterrupted access to life-saving sickle cell medications during this time. GBT is also working with ideaPoint to set up a new portal for stakeholders in the sickle cell community.
Specifically, GBT is using ideaPoint software to launch a new web-based portal for the sickle cell disease community – including non-profits, laboratories, and others affected by COVID-19. The ideaPoint portal is currently being used to accept grant applications as GBT recently set up a fund to support the sickle cell community.
Parexel International is a biopharma company headquartered in Waltham, Massachusetts. Parexel is working with ideaPoint to create a portal for a global Contract Research Organization (CRO), to provide support to healthcare, pharma, biotechnology, and medical device industries. The CRO will be used to gather ‘success stories’ running COVID-19 trials that can then be shared across the organization to see what is working and what is not.
With ideaPoint’s help, these three major companies – Abbott Laboratories, Global Blood Therapeutics, and PAREXEL – are helping drive innovation that can help develop better testing and treatment for COVID-19, a virus that has brought the entire world to a standstill. As partners to these companies, we are certain that their efforts will play a major role in future diagnostic testing and drug treatments to help manage and curb the spread of COVID-19, and remain committed to helping them in this international humanitarian goal.